MITO-BIOTHERAPEUTICS, INC.

Biotech · Private

Novel fusion protein that crosses the blood-brain barrier to deliver therapeutic payload for mitochondrial DNA repair in neurons

Grants
$275K
1 award
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantNational Science Foundation · Phase I · STTR Phase I: Novel Bio-Intervention to Attenuate Neurological Damage Following Traumatic Brain Injury$274,855
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2229Nimbus Therapeutics——
2230Inflection Medicine——
2231Tenvie——
2232MITO-BIOTHERAPEUTICS, INC.——
2233CREEGH PHARMACEUTICALS INC—$500K
2234Advac Therapeutic LLC——
2235I Peace, Inc.—$47M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.